Eloxatin®, Elplat®, Dacotin®, Dacplat®

A major advance in the history of cancer treatment

Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease.

In 2000’s approval of oxaliplatin in adjuvant settings has significantly increased the number of patients cured. It is a worldwide standard treatment in metastatic colorectal cancer.

Elplat and Eloxatin

In short

Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease.

It is a worldwide gold standard treatment in
metastatic & adjuvant colorectal cancer
metastatic & adjuvant pancreatic cancer

Overview of the products

Indications

  • Metastatic colorectal cancer
  • Adjuvant setting in colorectal cancer
  • Pancreatic cancer in USA and in Japan
  • Liver cancer in China

Product Characteristics

  • 3 dosages: 50mg – 100mg – 200mg
  • IV infusion
  • Freeze-dried and solution formulations

Debiopharm Value Added

  • Identification of the first clinical indication (mCRC)
  • Clinical development leading to the first file submission registration in France
  • Optimization of the efficacy-safety profile

Commercial map

Press Releases

All Press Releases

News

All News

Selected publications

All Publications